AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. (ANTX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
antx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for AN2 Therapeutics, Inc. (ANTX) measures how much investors pay for each dollar of the company's trailing earnings. ANTX's current PE ratio of N/A is calculated by dividing its stock price of $3.84 by its TTM earnings per share of -$1.01.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2019 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
AN2 Therapeutics, Inc.You ANTX | $105M | N/A | — | -$1.01 |
 Boundless Bio, Inc. BOLD | $32M | N/A | — | -$2.60 |
 iBio, Inc. IBIO | $28M | N/A | — | -$1.75 |
 Intensity Therapeutics, Inc. INTS | $7M | N/A | — | -$0.86 |
 Iterum Therapeutics plc ITRM | $2M | N/A | — | -$1.26 |
 NextCure, Inc. NXTC | $7M | N/A | — | -$19.65 |
 Pluri Inc. PLUR | $21M | N/A | — | -$3.56 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.16 | — | |
2024-12-31 FY2024 | — | $-1.72 | — | |
2023-12-31 FY2023 | — | $-2.74 | — | |
2022-12-31 FY2022 | — | $-2.67 | — | |
2021-12-31 FY2021 | — | $-1.15 | — | |
2020-12-31 FY2020 | — | $-0.73 | — | |
2019-12-31 FY2019 | — | $-1.80 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for AN2 Therapeutics, Inc. (ANTX) measures how much investors pay for each dollar of the company's trailing earnings. ANTX's current PE ratio of N/A is calculated by dividing its stock price of $3.84 by its TTM earnings per share of -$1.01.
Frequently asked questions
ANTX pe ratio · 6 questionsANTX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $3.84 and TTM EPS of -$1.01. Data sourced from Financial Modeling Prep via ANTX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · AN2 Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09